GI Dynamics, Inc. news

Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology

BOSTON — July 13, 2022 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier Registry and data from use within the Nat

Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints

Findings Presented at DDW 2022

BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a multicenter s

BOSTON & HYDERABAD, India--( )-- GI Dynamics Inc., a medical device company that isBUSINESS WIRE
developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to
announce that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India.

I-STEP is a multi-center, randomized, pivotal study evaluating the safety and efficacy of EndoBarrier® for glycemic
improvement in patients with inade

BOSTON — November 5, 2020 — GI Dynamics^® Inc. (“GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier^® for patients with type 2 diabetes and obesity, has appointed Joseph Virgilio as president and chief executive officer of GI Dynamics, Mark Lerdal as chairman of the Board of Directors (“the Board”) and Ginger Glaser as non-executive director to the

BOSTON — September 10, 2020 — GI Dynamics^® Inc. (‘GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier^® for patients with type 2 diabetes and obesity, is pleased to announce the initial closing of its private placement offering of Series A Preferred Stock led by Crystal Amber Fund Limited (“Crystal Amber”), the Company’s majority stockholder.

BOSTON and SYDNEY — 15 July 2020 — GI Dynamics^® Inc. (ASX:GID) (the “Company”), a medical device company that is developing EndoBarrier^® for patients with type 2 diabetes and obesity, advises that it has received a notice of conversion from Crystal Amber Fund Limited (“Crystal Amber”) (a Related Party for Australian Securities Exchange (“ASX”) purposes) of the Senior Secured Convert

BOSTON and SYDNEY — 15 July 2020 — GI Dynamics^® Inc. (ASX:GID) (the “Company”), a medical device company that is developing EndoBarrier^® for patients with type 2 diabetes and obesity, provides the following update regarding the removal of the Company from the Official List of the Australian Securities Exchange (“ASX”) (“Official List”).

Delisting from the Official Li

BOSTON and SYDNEY — 1 July 2020 — GI Dynamics^® Inc. (ASX:GID) (”the “Company”), a medical device company that is developing EndoBarrier^® for patients with type 2 diabetes and obesity, provides the following update regarding the extension of the maturity date of the Senior Secured Convertible Promissory Note issued to Crystal Amber Fund Limited (“Crystal Amber”), a Related Party for Austra

BOSTON and SYDNEY — 22 June 2020 — GI Dynamics^® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier^® for patients with type 2 diabetes and obesity, announces that it held its Special Meeting of Stockholders on 21 June 2020 and, in accordance with ASX Listing Rule 3.13.2, is pleased to confirm that each of the resolutions put to stockholders as set fo

BOSTON and SYDNEY — 19 June 2020 — GI Dynamics^® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier^® for patients with type 2 diabetes and obesity, is pleased to announce that it has issued a US$750,000 Unsecured Convertible Promissory Note to Crystal Amber Fund Limited (“Crystal Amber”), the Company’s largest stockholder and a Rela